Maxim Biomedical Plans to Market Millions of COVID-19 Tests This Year

Several biomedical industries are running to look for tests that will rapidly detect individuals infected with COVID-19. One of these biomedical companies is Maxim Biomedical. The company aims at producing millions of Maxim SARS-COV-2 Rapid Antigen Diagnostic Tests for COVID-19. The test is expected to be ready by the end of the year.

How the test operates

The test will use the Lateral Flow Assay (“LFA”) technology with a sleek workflow and a closed-tube format to avoid the need for a reader or an expensive tool to perform. Its patent, awaiting approval, contains the reagents, specimen swab, and test strip compacted in a self-enclosed environment. This design is intended to enable the incubation, reading, and disposal in one tube.

Additionally, the test has been made in a way that will give the results after fifteen minutes from the time the sample has been collected. The results will also be reviewed after two hours, and it has been seen that it’s a longer period than how most LFA tests work. Maxim Biomedical is also committed to producing high-quality testing kits to fulfill unmet needs by other existing testing kits. It is also a good chance for Maxim to apply its expertise in LFA’s application to protect the community and frontline workers from the risks of contracting the disease during the testing time.

Development of the test

The Maxim Rapid Antigen Diagnostic Test for SARS-COV-2 was developed as part of the Rapid Acceleration of Diagnostics (RADxSM) action in collaboration with the National Institute of Health. The firm is aiming at producing over one million tests every month by the end of this year. Moreover, its vision is to produce more than fifteen million tests every month at the beginning of next year. Maxim Biomedical has also signed a deal with TEAM Technologies to manufacture more tests.

Final verdict

If all the plans are worked on in time, then the Rapid Antigen Diagnostic Test will hit the market before the year ends. It will be a good move to curb the virus as the results will be available in time to enable the infected persons to be put into isolation and undergo treatment. Besides, more tests will also be conducted in a short period to help identify asymptomatic cases. It will also help countries to come up with other safety measures to help in flattening the curve of the pandemic.

Every effort counts, and biomedical companies like 180 Life Sciences Corp. are expected to welcome the work done by Maxim as this effort contributes towards removing a threat that has brought to world to its knees.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.